MedTrace Logo

The Effect of Colostrum Bovinum Supplementation in Endurance Athletes

NCT06390670 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-04-30

No results posted yet for this study

Summary

The purpose of this study was to verify the effect of chronic 12-week high-dose Colostrum Bovinum (COL) and placebo (PLA) supplementation on immunological, hematological and biochemical markers, as well as physical capacity and discipline-specific exercise performance in endurance athletes, in a randomized, double-blind, placebo-controlled crossover trial.

Conditions

  • Sports Nutrition
  • Biochemical Markers
  • Exercise Performance
  • Aerobic Capacity
  • Supplementation

Interventions

DIETARY_SUPPLEMENT

Colostrum Bovinum supplementation

In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.

OTHER

Placebo treatment

In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.

Sponsors & Collaborators

  • Nutricia Foundation

    collaborator OTHER

  • Poznan University of Life Sciences

    collaborator OTHER

  • Poznan University of Physical Education

    lead OTHER

Principal Investigators

  • Krzysztof Durkalec-Michalski, Prof., PhD · Poznan University of Physical Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2023-03-01
Completion
2024-03-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06390670 on ClinicalTrials.gov